Avicenna J Med Biotech

arij002

Avicenna Journal of Medical Biotechnology

2008-2835 2008-4625

Avicenna Research Institute

ajmb60599

Comparison of Anticancer Effects between Platinum Levetiracetam and Platinum Azidothymidine through the Expression of Biomarker Genes on Cancer Cell Lines

Sabokrouh

Abdolreza

Department of Molecular Medicine & Genetics, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran

Ghaffari

Nasim

Karimi Tafreshi

Zahra

Atabi

Freshteh

Sharifi

Zohreh

Department of Pharmaceutical Biotechnology, Faculty of Pharmacy and Biotechnology Research Center, Tehran University of Medical Sciences, Tehran, Iran

Shokouhi Mostafavi

Seyyed Khalil

17 1 24 30 14 6 2024 2 10 2024

Background: The utilization of biomarkers is a way to assess the efficacy of recently created anticancer drugs. MiRNAs, telomerase, and Bcl-2 are extensively utilized as biomarkers for this purpose. This study aims to evaluate the comparison of the newly synthesized platinum compounds such as Platinum Azidothymidine (Pt-AZT) with Platinum Levetiracetam (Pt-Lev) on HepG2 cancer cell lines via the biomarkers. Methods: In this study, cells were divided into four groups: Group A (HDF cells) were the normal negative control group, group B were HepG2 untreated cancer cells, and groups C and D were treated cancer cells with Pt-AZT and Pt-Lev, respectively. After evaluating the LC50 for the drugs by MTT test, the relative gene expression of the biomarkers was determined by qPCR. Results: The results showed a significant decrease for antiapoptotic genes including miRNA-21 (5.1±0.014), telomerase (0.56±0.48), Bcl-2 (0.41±0.276) in group D, whereas in group C was more than group D for miRNA-21 (6.0±0.141), telomerase (3.49±0.231), Bcl-2 (4.93±0.276) also there was a significant increase in miRNA-122 (33.97±0.04) in group D, whereas in group C was (28.36±0.007) and so lower than group D. Most of the investigated groups showed a significant difference (p<0.05). In addition, there were widespread apoptotic regions in Pt-Lev treatment compared to Pt-AZT. Conclusion: The advantages of using Pt-Lev were more powerful anticancer effects on biomarkers through inhibition of antiapoptotic and stimulation proapoptotic factors and also lower side effects and lower drug resistance than Pt-AZT; therefore, it can be considered a more effective anti-cancer therapy.